Publications from the National Academies of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes Health and Medicine Division (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.
Fungal Diseases: An Emerging Threat To Human, Animal, and ...
Released: September 09, 2011
Fungal diseases have contributed to death and disability in humans, triggered global wildlife extinctions and population declines, devastated agricultural crops, and altered forest ecosystem dynamics. Despite the extensive influence of fungi on health and economic well-being, the threats posed by emerging fungal pathogens to life on Earth are often underappreciated and poorly understood. On December 14 and 15, 2010, the IOM’s Forum on Microbial Threats hosted a public workshop to explore the scientific and policy dimensions associated with the causes and consequences of emerging fungal diseases.
Adverse Effects of Vaccines: Evidence and Causality : Health ...
Released: August 25, 2011
Immunizations are a cornerstone of the nation’s efforts to protect people from a host of infectious diseases. Though generally very rare or very minor, there are side effects, or “adverse effects,” associated with some vaccines. The IOM reviewed a list of adverse events associated with eight vaccines to evaluate the scientific evidence about the event–vaccine relationship. Using epidemiologic and mechanistic evidence, the committee developed 158 causality conclusions, assigning each relationship between a vaccine and an adverse health problem to one of four causation categories. Overall, the IOM committee concludes that few health problems are caused by or clearly associated with vaccines.
A Nationwide Framework for Surveillance of Cardiovascular ...
Released: July 22, 2011
Surveillance systems have a potentially key role in reducing the health toll of chronic diseases. Currently, surveillance data are collected from a variety of sources, but there is no national surveillance system to fill the gaps between these monitoring approaches. To help close the gap, the IOM presents a conceptual framework for national surveillance of cardiovascular and chronic lung disease and calls on the Department of Health and Human Services to adopt it and take the lead in developing a national surveillance system.
Implementing a National Cancer Clinical Trials System for the ...
Released: July 22, 2011
The National Cancer Institute’s Clinical Trials Cooperative Group Program works to advance patient care and research. Despite broad participation in the program, financial strain and procedural burdens limit the ability of the Cooperative Group Program to undertake medical practice-changing clinical research. The IOM’s National Cancer Policy Forum and the American Society of Clinical Oncology held a workshop on March 21, 2011 to follow up on the 2010 IOM report A National Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program, which made recommendations to strengthen the NCI Cooperative Group Program.
Patient-Centered Cancer Treatment Planning: Improving the ...
Released: June 13, 2011
The life-threatening nature of cancer and the complexity of cancer treatment options, each with its own set of potential risks and benefits, make it difficult for people with cancer to make decisions about their care. A cancer treatment plan—a written document describing the path of care and who is responsible for each portion of that care—can provide patients with a roadmap to navigate the uncertain path they face. However, most providers lack the tools, time, and resources needed to efficiently and effectively prepare such plans with their patients. The IOM’s National Cancer Policy Forum held a workshop to discuss ways to create a more coordinated, patient-centered cancer treatment planning process.
Glutamate-Related Biomarkers in Drug Development for ...
Released: June 08, 2011
Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer’s, substance abuse, and traumatic brain injury. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The IOM’s Forum on Neuroscience and Nervous System Disorders held a workshop June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers.
The Causes and Impacts of Neglected Tropical and Zoonotic ...
Released: June 01, 2011
Neglected tropical diseases (NTDs) afflict more than 1.4 billion people, many of whom live on less than $1.25 a day. While there are effective ways to manage NTDs, policy-makers and funders have only recently begun to recognize the economic and public health importance of controlling NTDs. The IOM’s Forum on Microbial Threats held a workshop September 21-22, 2010, to discuss the science of and policy surrounding NTDs.
Critical Needs and Gaps in Understanding Prevention ...
Released: April 20, 2011
A single tick bite can have debilitating consequences. Lyme disease is the most common disease carried by ticks in the United States, and the number of those afflicted is growing steadily. If left untreated, the diseases carried by ticks—known as tick-borne diseases—can cause severe pain, fatigue, neurological problems, and other serious health problems. The IOM held a workshop October 11-12, 2010, to examine the state of the science in Lyme disease and other tick-borne diseases.
The National Cancer Policy Summit: Opportunities and ...
Released: February 28, 2011
Technological advances are altering the way cancer research is conducted and cancer care is delivered, and research increasingly is an international effort. At the same time, research budgets are shrinking and the cost of care is growing. The National Cancer Policy Summit brought together leaders in the cancer community to discuss these changes in research and care. Participants suggested many potential actions to provide more patient-centered cancer care, foster more collaboration, and achieve other goals to improve research and care.
Nanotechnology and Oncology – Workshop Summary : Health ...
Released: February 25, 2011
One way scientists are working to overcome challenges in cancer treatment and improve cancer care is through nanotechnology. The National Cancer Policy Forum held a workshop July 12-13, 2010, to explore challenges in the use of nanotechnology in oncology.